Recurrence of Metastatic Pro-insulinoma Nearly 50 Years After Subtotal Pancreatectomy

  • Minerva A. Romero Arenas
  • Courtney Olsen
  • James C. Yao
Case Report
  • 20 Downloads

Notes

Compliance with ethical standards

Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Conflict of interest

James Yao is a consultant for Novartis, Ipsen. The remaining authors declare that they have no conflict of interest.

References

  1. 1.
    Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66(7):711–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Whipple AO, Frantz VK. Adenoma of islet cells with hyperinsulinism: a review. Ann Surg. 1935;101(6):1299–335.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Scarlett JA, Mako ME, Rubenstein AH, et al. Factitious hypoglycemia. Diagnosis by measurement of serum C-peptide immunoreactivity and insulin-binding antibodies. N Engl J Med. 1977;297(19):1029–32.CrossRefPubMedGoogle Scholar
  4. 4.
    Gomez-Perez FJ, Cuevas-Ramos D, Valdes PA, Aguilar-Salinas CA, Mehta R, Rull JA. Beta-cell adenomas without hyperinsulinemia with use of highly specific insulin radioimmunoassays: case report and review of literature. Endocr Pract. 2010;16:660–3.CrossRefPubMedGoogle Scholar
  5. 5.
    Clark G, Sadur C, Puligandla B. Multiple proinsulinsecreting tumors of the pancreas treated by laparoscopic distal pancreatectomy and splenectomy. World J Surg. 2009;33(3):397–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Piovesan A, Pia A, Visconti G, et al. Proinsulin-secreting neuroendocrine tumor of the pancreas. J Endocrinol Investig. 2003;26(8):758–61.CrossRefGoogle Scholar
  7. 7.
    Gury H, Rio F, Neamtu D, Boivin S. Insulinoma with hyperproinsulinemia: a two cases report. Ann Endocrino (Paris). 2002;63(3):240–2.Google Scholar
  8. 8.
    Murtha TD, Lupsa BC, Majumdar S, Jain D, Salem RR. A systematic review of proinsulin-secreting pancreatic neuroendocrine tumors. J Gastroint Surg. 2017;21(8):1335–41.CrossRefGoogle Scholar
  9. 9.
    Crippa S, Zerbi A, Boninsegna L, Capitanio V, Partelli S, Balzano G, et al. Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections. Arch Surg. 2012;147(3):261–6.Google Scholar
  10. 10.
    Tsang YP, Lang BH, Shek TW. Assessing the short- and long-term outcomes after resection of benign insulinoma. ANZ J Surg. 2016;86(9):706–10.CrossRefPubMedGoogle Scholar
  11. 11.
    Nikfarjam M, Warshaw AL, Axelrod L, Deshpande V, Thayer SP, Ferrone CR, et al. Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg. 2008;247(1):165–72.Google Scholar
  12. 12.
    Yao J, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase III study. Lancet. 2016;387:968–77.CrossRefPubMedGoogle Scholar
  13. 13.
    Yao J, Shah M, Ito T, Bohas C, Wolin E, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Chan DL, Segelov E, Singh S. Everolimus in the management of metastatic neuroendocrine tumours. Ther Adv Gastroenterol. 2017;10(1):132–41.CrossRefGoogle Scholar
  15. 15.
    Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009;360(2):195–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Ohmoto A, Rokutan H, Yachida S. Pancreatic neuroendocrine neoplasms: basic biology, current treatment strategies and prospects for the future. Chellappan S, Padmanabhan J, eds. Int J Mol Sci. 2017;18(1):143.Google Scholar
  17. 17.
    Deberg M, Houssa P, Frank B, Sodoyez-Goffaux F, Sodoyez JC. Highly specific radioimmunoassay for human insulin based on immune exclusion of all insulin precursors. Clin Chem. 1998;44:1504–13.PubMedGoogle Scholar
  18. 18.
    Rodriguez A, Cnato MI, Makary MA. Endoscopic localization and tattooing of a proinsulinoma for minimally invasive resection. Pancreas. 2011;40(3):474–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Bartsch DK, Albers M, Knoop R, Kann PH, Fendrich V, Waldmann J. Enucleation and limited pancreatic resection provide long-term cure for insulinoma in multiple endocrine neoplasia type 1. Neuroendocrinology. 2013;98(4):290–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Qin SY, Lu XP, Jiang HX. EUS-guided ethanol ablation of insulinomas: case series and literature review. Medicine (Baltimore). 2014;93(14):e85.CrossRefGoogle Scholar
  21. 21.
    Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.Google Scholar
  22. 22.
    Simon D, Starke A, Goretzki PE, Roeher HD. Reoperative surgery for organic hyperinsuinism: indications and operative strategy. World J Surg. 1998;22:666–72.CrossRefPubMedGoogle Scholar
  23. 23.
    Zhan HX, Cong L, Zhao YP, et al. Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis. J Surg Oncology. 2012;106:972–80.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Minerva A. Romero Arenas
    • 1
  • Courtney Olsen
    • 1
  • James C. Yao
    • 2
  1. 1.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Gastrointestinal Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations